Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) Net Margin (2019 - 2026)

Biodesix filings provide 8 years of Net Margin readings, the most recent being 32.0% for Q1 2026.

  • On a quarterly basis, Net Margin rose 2826.0% to 32.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 34.28%, a 1947.0% increase, with the full-year FY2025 number at 40.21%, up 1973.0% from a year prior.
  • Net Margin hit 32.0% in Q1 2026 for Biodesix, down from 14.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 14.0% in Q4 2025 to a low of 238.21% in Q1 2022.
  • Median Net Margin over the past 5 years was 62.71% (2023), compared with a mean of 91.65%.
  • Biggest five-year swings in Net Margin: tumbled -21661bps in 2022 and later skyrocketed 11576bps in 2024.
  • Biodesix's Net Margin stood at 171.13% in 2022, then skyrocketed by 63bps to 62.71% in 2023, then skyrocketed by 34bps to 41.12% in 2024, then soared by 66bps to 14.0% in 2025, then crashed by -129bps to 32.0% in 2026.
  • The last three reported values for Net Margin were 32.0% (Q1 2026), 14.0% (Q4 2025), and 41.92% (Q3 2025) per Business Quant data.